Q-omics provides the consensus-scored TADA2A profile across patient tissues and cancer cell-line models. TADA2A expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TADA2A is differentially expressed in 14, with the highest sampling consensus in THCA. Additionally, TADA2A RNA expression shows 20,991 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and THCA as cancer lineages where TADA2A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TADA2A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TADA2A survival associations across molecular data types. TADA2A RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TADA2A RNA expression–survival associations across cancer types. High TADA2A expression shows unfavorable associations in ACC, KIRC, LIHC and MESO, but favorable associations in SCLC and UCEC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for TADA2A RNA expression.
This table summarizes TADA2A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 2. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TADA2A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TADA2A shows lower tumor expression in THCA and KICH and higher tumor expression in HNSC, COAD, LIHC and BLCA. The THCA box plot shows higher TADA2A RNA expression in normal versus tumor tissue (log2 FC = −0.782, t-test p < 0.001).
This table shows molecular features associated with TADA2A in patient tissues and cancer cell lines. In patient samples, TADA2A shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TADA2A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
